Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
20
06
2022
accepted:
29
09
2022
entrez:
11
10
2022
pubmed:
12
10
2022
medline:
14
10
2022
Statut:
epublish
Résumé
This retrospective study aimed to evaluate choroidal hemodynamics after half-dose photodynamic therapy (PDT) for central serous chorioretinopathy (CSC) and the effects of smoking using laser speckle flowgraphy. This study included 29 eyes of 29 patients treated with half-dose PDT for CSC, who were followed-up for at least 6 months. The mean blur rate (MBR) in the PDT irradiation area (whole area), the pachyvessel (PV) area, non-PV (NPV) area, and filling delay (FD) area were assessed at baseline and 1, 3, and 6 months post-PDT, respectively. The MBR was also assessed by smoking status. The MBR significantly decreased from baseline in the whole, PV, NPV, and FD areas at all time points (P < 0.001). Of the 29 patients, 6 were never smokers, 13 were past smokers, and 10 were current smokers. At baseline, no significant difference was found in the MBR in the whole, PV, NPV, and FD areas among never, past, and current smokers. The MBR changes showed a significantly smaller decrease in current smokers than in never smokers in the whole (P = 0.021), PV (P = 0.009), and NPV (P = 0.034) areas, but not in the FD area (P = 0.172). Half-dose PDT for CSC reduced choroidal blood flow in the PDT-irradiated area, which was blunted by current smoking status.
Identifiants
pubmed: 36220845
doi: 10.1038/s41598-022-21584-8
pii: 10.1038/s41598-022-21584-8
pmc: PMC9553890
doi:
Substances chimiques
Photosensitizing Agents
0
Verteporfin
0X9PA28K43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17032Informations de copyright
© 2022. The Author(s).
Références
Prog Retin Eye Res. 2022 Jan;86:100973
pubmed: 34029721
Retina. 2016 May;36(5):986-91
pubmed: 27115859
Ophthalmic Surg Lasers Imaging Retina. 2015 May;46(5):561-5
pubmed: 26057759
Br J Ophthalmol. 2013 Jun;97(6):775-80
pubmed: 23532615
PLoS One. 2017 Jul 24;12(7):e0181479
pubmed: 28742138
Retina. 2008 Jan;28(1):85-93
pubmed: 18185143
PLoS One. 2021 Mar 23;16(3):e0249073
pubmed: 33755707
Ophthalmic Res. 2021;64(6):1037-1047
pubmed: 34510043
Ophthalmol Retina. 2020 Sep;4(9):938-945
pubmed: 32651158
Eye (Lond). 2012 May;26(5):640-9
pubmed: 22573069
Sci Rep. 2020 Jun 12;10(1):9591
pubmed: 32533066
Invest Ophthalmol Vis Sci. 2014 Jun 03;55(6):3893-9
pubmed: 24894395
Invest Ophthalmol Vis Sci. 2013 Nov 21;54(12):7699-706
pubmed: 24130177
Sci Rep. 2018 Sep 20;8(1):14128
pubmed: 30237467
Br J Ophthalmol. 2017 Apr;101(4):433-437
pubmed: 27388248
Am J Ophthalmol Case Rep. 2020 Mar 05;18:100651
pubmed: 32215340
Retina. 2009 Nov-Dec;29(10):1469-73
pubmed: 19898183
Ophthalmology. 2015 Mar;122(3):555-61
pubmed: 25444637
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6515-22
pubmed: 26447987
Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1316-1320
pubmed: 30943279
Ophthalmol Retina. 2021 Mar;5(3):285-291
pubmed: 32683110
Br J Ophthalmol. 2018 Apr;102(4):473-478
pubmed: 28779008
Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1195-200
pubmed: 26887825
BMC Ophthalmol. 2021 May 31;21(1):241
pubmed: 34053440
Microvasc Res. 2000 Nov;60(3):281-93
pubmed: 11078644
Br J Ophthalmol. 2019 Jun;103(6):725-729
pubmed: 30002072
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):227-229
pubmed: 28889224
Arch Ophthalmol. 2003 Feb;121(2):225-31
pubmed: 12583789
Jpn J Ophthalmol. 2017 May;61(3):260-266
pubmed: 28154953
Br J Ophthalmol. 2006 Jul;90(7):869-74
pubmed: 16597666
Retina. 2016 Sep;36(9):1646-51
pubmed: 27124882
Retina. 2016 Sep;36(9):1652-7
pubmed: 26934451
Am J Ophthalmol. 2020 Sep;217:104-113
pubmed: 32360342
Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):748-57
pubmed: 12271373